Saudi FDA Launches NADR Program to Accelerate Rare Disease Drug Development
核心洞察
The Saudi Food and Drug Authority (搜索) (SFDA) has launched the New Accelerator Program for Drugs in Rare Diseases (搜索) (NADR) to streamline development, evaluation, and authorization of rare disease medicines.
NADR targets drugs for conditions affecting fewer than 5 in 10,000 people in Saudi Arabia where no satisfactory treatment exists or where the product offers significant clinical benefit.
The program accepts flexible clinical evidence including adaptive trial designs, natural history data, surrogate endpoints, and new approach methodologies such as AI and organ-on-a-chip models.
The Saudi Food and Drug Authority (搜索) (SFDA) has launched the New Accelerator Program for Drugs in Rare Diseases (搜索) (NADR), a specialized initiative designed to streamline the development, evaluation, and authorization of medicines for rare diseases. The program aims to accelerate patient access to critical treatments while strengthening Saudi Arabia's position among leading countries supporting research and innovative healthcare solutions.
Program Scope and Eligibility
According to the SFDA, the NADR designation applies to drugs intended to prevent or treat rare diseases (搜索), defined as conditions affecting fewer than 5 in 10,000 people in Saudi Arabia. To qualify, either no satisfactory treatment must currently exist in Saudi Arabia, or the product must offer a significant clinical benefit over available therapeutic options.
Products may be under active development at any stage or already authorized by another regulatory authority but not yet registered in Saudi Arabia. The SFDA emphasized that facilitating timely access to medicines for patients with rare diseases (搜索) remains a key priority.
Flexible Approaches to Clinical Evidence
The SFDA will offer "flexible and innovative approaches to the evaluation of clinical evidence that take into account the challenges associated with small patient populations." In guidance on the NADR, the agency named adaptive trial designs among the types of evidence it will accept for rare disease filings, including Bayesian adaptive, N-of-1, basket, umbrella, and platform studies, "that maximize information yield from small patient samples."
The SFDA will also accept natural history data, modeling and simulation outputs, surrogate endpoints, and knowledge of platform technologies. New approach methodologies (NAM) are likewise acceptable, including data derived from artificial intelligence, machine learning, and in silico computational models, as well as from organ-on-a-chip in vitro models. The agency plans to publish dedicated guidance on NAMs in 2026 or 2027.
Regulatory Incentives and Support
Eligible drugs benefit from regulatory incentives and support measures, including dedicated scientific and regulatory guidance. The SFDA will apply a proportionate evidence approach to periodic safety update reports and registries, "tailoring requirements to the specific patient population size to ensure technical feasibility and encourage industry compliance."
The flexibility extends to exemptions from chemistry, manufacturing, and controls data requirements, including provisions to accelerate production site registration. The program also provides flexibility in procedures for manufacturer site registration and inspection, as well as support regarding periodic safety reports.
Application Process and Timelines
Companies interested in participating in the program should organize a presubmission meeting with the SFDA. Applicants without an orphan drug designation (ODD) can request that status in parallel to applying for the NADR. The agency will review NADR and ODD requests within 20 working days of receiving the complete submission. Companies will then have six months to apply for marketing authorization.
The launch of NADR forms part of the SFDA's broader efforts to expand access to rare disease treatments, support comprehensive healthcare for patients in Saudi Arabia, and enhance their overall quality of life.